MANILA, Philippines — Patuloy ang paalala ng Department of Health (DOH) sa publiko maging sa mga indibidwal na nakakumpleto na ng dalawang dosage ng COVID-19 vaccines na mag-ingat dahil posible pa...
MANILA, Philippines – A total of 1.5 million doses of COVID-19 vaccines from Sinovac and Gamaleya Institute are expected to arrive in the country within this month, vaccine czar and...
MANILA, Philippines — Vaccination among senior citizens kicked off today (April 12) using China’s Sinovac vaccine CoronaVac. In San Juan City, vaccine confidence among the elderly sector increased after they received...
MANILA, Philippines – An additional 500,000 doses of novel coronavirus disease (COVID-19) vaccines developed by Chinese drug maker Sinovac BioTech have been delivered in the Philippines. Flag carrier Philippine Airlines...
MANILA, Philippines – Shipments containing two million doses of coronavirus disease (COVID-19) vaccines are expected to arrive in the Philippines in April or May, Malacañang said. In a statement issued...
MANILA, Philippines – The Food and Drug Administration (FDA) on Wednesday announced that it has approved the use of CoronaVac COVID-19 vaccine, developed by China’s Sinovac BioTech, on senior citizens....
MANILA, Philippines — The country’s vaccine expert panel has recommended the use of CoronaVac, the COVID-19 vaccine produced by China’s Sinovac BioTech, for individuals aged 60 years old and above....
MANILA, Philippines – At least two million doses of COVID-19 vaccines are expected to arrive in the Philippines this month, vaccine czar and National Task Force against COVID-19 chief implementer...
MANILA, Philippines – The one million doses of COVID-19 vaccine developed by Chinese firm Sinovac BioTech arrived in Manila on Monday, making it the first government-procured vaccine supply to be...
MANILA, Philippines – The second batch of Sinovac BioTech’s coronavirus vaccine, CoronaVac donated by China arrived at the Ninoy Aquino International Airport (NAIA) on Wednesday. The Philippine Airlines flight...
